News and Events

News

10.24.24

Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor

4.8.24

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting

3.21.24

Accent Therapeutics to Present Data Supporting DHX9 and KIF18A as Compelling Therapeutic Targets at American Association for Cancer Research (AACR) Annual Meeting 2024

1.23.24

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies

10.10.23

Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium

9.21.23

Accent Therapeutics Bolsters Leadership Team with Key Executive Hires

4.16.23

Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

4.6.23

Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

Events

AACR: RNAs as Drivers, Targets and Therapeutics in Cancer

November 14-17, 2024, Bellevue, Washington

RNA-Targeted Drug Discovery and Development Summit

December 10-12, 2024, Boston, Massachusetts